Many patients with chronic obstructive airways disease (COAD) receive therapy by the inhaled route. This study was performed to assess whether patients with severe COAD could generate sufficient peak inspiratory flow (PIF) through Turbuhalera (Astra, Sodertalje) to operate it effectively.
Introduction
Bronchodilator therapy by the inhaled route is now established as preferable to oral therapy in both chronic obstructive airways disease (COAD) and asthma. Also, anticholinergic bronchodilators are available only for inhalation and are often used in the treatment of COAD as well as inhaled &adrenoreceptor agonists such as salbutamol and terbutaline. Many patients with COAD are elderly and are often unable to achieve coordination of inspiration and actuation when using a conventional pressurized metered dose inhaler (1) . Turbuhaler@ (Astra, Sodertalje) is an inspiratory flow driven dry powder device which can be used in preference to the pMD1 (2-4) and does not contain lubricants or propellants, which in themselves can cause bronchoconstriction (5-7). An inspiratory flow rate of 228 lmin-' through the Turbuhaler@ should be generated to operate it effectively (8) . This can be achieved by all asthmatic adults (9), children aged 6 years or more (8) and 98% of asthmatic patients with a severe exacerbation requiring hospitalization (10 This study was designed to assess whether patients with COAD can generate sufficient inspiratory flow to use Turbuhalera effectively. A second aim was to assess if other lung function variables could be used to predict peak inspiratory flow through TurbuhaleP (PIF-T).
Methods
The study was approved by the local ethics committee and conducted in accordance with the guidelines of the declaration of Helsinki. All patients gave written informed consent.
One hundred and ten patients, aged 2 18 years, with a confirmed diagnosis of COAD were screened either in hospital or in the outpatient clinic. One hundred patients (45 men, 55 women, mean age 69.1 years) fulfilled the selection criteria [peak expiratory flow (PEF) 1200 1 min- ' or forced expiratory volume in 1 set (FEV,) I 1 litre]. Thirty-seven were inpatients following an acute exacerbation of COAD. Sixty-six were previous smokers, eight occasional smokers, 19 habitual smokers and seven had never smoked. Mean (SD) duration of COAD was 17.7 (16.3) years.
Within 48 h of screening, the patients underwent a series of inspiratory and expiratory lung function measurements. The order of these tests (inspiratory vs. expiratory) was Ltd., Buckingham, U.K.). A maximal forced expiration was performed, from which the FEV,, forced vital capacity (FVC) and forced expiratory flow between 25% and 75% of FVC (FEF,,-,,) were derived. PEF was measured using a Vitalograph peak expiratory flow meter with absolute scale. A maximal forced expiration immediately followed by a maximal forced inspiration was performed to measure the peak inspiratory flow without Turbuhalerm (PIF) from the inspiratory limb of the flow volume loop. Peak inspiratory flow through empty Turbuhalerm (PIF-T) was then measured during a maximal forced inspiration using another spirometer attached to an adaptor in which an empty Turbuhaler@ was mounted. Noseclips were used for both inspiratory measurements and for all variables the best of three measurements was used for analysis. Relationships between variables were analysed statistically using Pearson product moment correlation tests. patients with diminished lung function may have been unable to operate Turbuhaler@ effectively. This study was carried out to address this concern.
From the results it is apparent that patients with COAD selected for the study were all able to generate a PIF-T of greater than 28 1 min -'. This is sufficient to operate Turbuhalera effectively and receive a therapeutically active amount of bronchodilator drug to the airways. Significant correlations were found between inspiratory and expiratory flow rates, but these were too weak to allow PIF or PIF-T to be predicted from either PEF or FEV,. The correlation coefficients found for PIF and expiratory flow rates were lower than those obtained by Brown et al. (10) in 99 adult patients presenting to hospital with acute exacerbations of asthma and by Engel et al. in outpatients with asthma (11) . The latter study examined 101 adults with less severe airways obstruction (mean FEV, =2.4 1) and similarly found a weak relationship between expiratory flow rates and PIF. This study also found that FEV, was less well correlated with PIF-T than with PIF. In contrast to Engel's study, we found that there was slightly more correlation between PEF and PIF-T than with PIF. However, the overall findings are the same and confirm that both expiratory lung function measurements and standardly measured PIF cannot predict PIF-T through TurbuhaleP.
In summary, this study demonstrates that patients with COAD with low expiratory flow can use Turbuhalera effectively. These findings are in line with those for patients with acute and moderate to severe asthma.
